This committee’s site publishes no list of positions we could read, and we found no statement of why it exists. We do not write one for it.
Who it gives toWhich candidates and committees get its money?
Each part reads different filings, so counts and totals can differ.
Party support distribution$183K to 56 candidates
Direct PAC contributions and independent expenditures explicitly reported as support, by the party of the candidate they went to.
For candidates $183,000
Republican 57%
Democratic 33%
Support by the party of the candidate
Party of the candidate
Candidates
Direct
Independent
Amount
Share
Republican
30
$104,500
$0
$104,500
57%
Democratic
19
$60,500
$0
$60,500
33%
Other or unresolved
7
$18,000
$0
$18,000
9.8%
Shown support
56
$183,000
$0
$183,000
100%
Contributions are reported money, not endorsements; a PAC giving to both parties is common.
Who this PAC gave to$277,000 in 139 payments
Every contribution on line 23 of the committee’s own Schedule B, which is the filing its summary totals are built from. That line covers federal candidates, party committees and other political committees alike, so a super PAC funding other super PACs appears here rather than under candidate giving.
By recipient
Line 23 contributions by kind and party of recipient
Recipient
Count
Amount
Democratic candidates
19
$60.5K · 22%
Republican candidates
30
$104.5K · 38%
Other or unresolved candidates
8
$19K · 6.9%
Other PACs and committees
23
$93K · 34%
All recipients
80
$277K
By the candidate’s state
Contributions to candidates by the candidate’s state
State
Candidates
Amount
Texas
10
$48K
Florida
4
$15K
Washington
3
$12.8K
Massachusetts
3
$11.8K
California
5
$11K
Alabama
1
$10K
Kentucky
1
$10K
Pennsylvania
2
$9K
The largest 8 of 27 states.
Recipients 80
Show candidate activity and the money network
Candidate and election activity as the recipients filed it
John Cornyn2 receipts, latest Mar 11, 2026Texans for Senator John Cornyn Inc. · S2TX00106$10K
Terri A. Sewell4 receipts, latest Jun 16, 2026Terri Sewell for Congress · H0AL07086$10K
John Kevin Ellzey Sr.4 receipts, latest Jun 11, 2026Jake Ellzey for Congress · H8TX06266$10K
Elizabeth Ann Van Duyne4 receipts, latest Jun 11, 2026Beth VAN Duyne for Congress · H0TX24209$10K
S. Brett Brett Guthrie2 receipts, latest Mar 26, 2026Guthrie for Congress · H8KY02031$10K
Candidate contribution rows come from candidate committee Schedule A filings, the same rows the party chart above counts.
Committee money network
Money moving between this committee and other committees, matched on FEC committee ID rather than the name each filing was typed under. Both sides exclude memo entries. The figures here count each committee once, from the itemized transfers read for this section, so they will not match the payment counts under Who this PAC gave to.
Committees funding this one
Committees that reported giving to this one on their own Schedule A filings, grouped by the giver’s committee ID.
No committee-to-committee receipts were itemized this cycle.
Committees this one funds
Disbursements this committee itemized to another committee: candidate contributions, party transfers and payments alike, not contributions only.
Brian Day5 contributions, latest Sep 30, 2026 · SVP, COMMERCIAL OPERATIONS · VIZIENT, INC. · DENVER, CO$3,750
A donor who gave several times appears once. The 12 largest donors by total given are listed. In all, 566 itemized contributions were filed this cycle, totaling $229.9K. FEC contributor lists are public records and cannot be used for commercial solicitation.
Unitemized ($200 or less)Donors who have given $200 or less this cycle, so the FEC does not itemize (name) them.$28,49011%
Refunds and rebatesMoney coming back to the committee: rebates and refunds of what it spent, contributions it made that were returned, and loans it made that were repaid.$2,5001%
Total reported receipts $260,913
Every dollar the committee reported receiving this cycle, split by the source the FEC filing attributes it to. Open a source marked + to see who gave. FEC filings through Sep 30, 2026.
Who donated: where they live, their employers and jobs
Where the donors live $229,771 placed by state
Loading the map
Tap or hover over a state, or focus the map and use the arrow keys, to read its total. Ctrl or ⌘ and scroll to zoom.
under $3.1K
$3.1K+
$12.3K+
$27.7K+
$49.2K+
none
Top states
Top donor states
Name
Amount
Texas174 contributions · 33%
$76,837
Illinois101 contributions · 20%
$47,023
Georgia14 contributions · 5.2%
$11,925
Minnesota27 contributions · 3.9%
$8,905
SpendingWhere does the money go?
How the spending splits $279,500 reported
Contributions to candidates and other committeesMoney given to federal candidates, party committees and other PACs.$279,500100%
People For Ben2 payments · latest Sep 23, 2026 · CONTRIBUTION$6,000
Total reported disbursements $279,500
Every dollar this committee reported spending this cycle, split by the lines it reports against. Open a line to see who was actually paid on it. FEC filings through Sep 30, 2026.
What the payments were for $277,000 itemized
Given to othersContributions to other candidates, party committees, and PACs.$277,000100%
Filed as
CONTRIBUTION$277,000
Paid to
Republican Mainstreet Partnership PAC$10,000
Elect Democratic Women$10,000
Future Forum PAC$10,000
New Democrat Coalition Action Fund$10,000
Terri Sewell for Congress$10,000
Texans for Senator John Cornyn Inc.$10,000
Total itemized disbursements $277,000
Every itemized payment the committee reported this cycle, sorted by what it said each one was for. The categories are ours; the wording they are matched against is the committee’s own. Open a category to read the filed descriptions and who was paid. FEC filings through Sep 30, 2026.
All 139 itemized payments filed this cycle. Spending below the itemization threshold is not filed line by line.
$279.5K spent from Jan 2025 to Sep 2026. Most in one report: $72.3K, Jan 1 – Jun 30, 2025.
$279.5K
Jan 2025Sep 2026
The running total of what the committee’s FEC reports say it spent, independent expenditures included, with a point at the end of each report. The line is straight between reports because a report gives one total for its whole period.
Besides giving through its PAC, Vizient, Inc. pays lobbyists to press Congress and federal agencies. Each quarter it, or a firm it hires, files a public report under the Lobbying Disclosure Act saying which topics it worked on, what it spent, and whom it contacted. This is what those reports say.
Spent on lobbying in 2026
$940K
Quarterly reports read
9
Bills it named
18
Topics it lobbied on
Each report files its work under official topics. The bar shows how often each topic came up across the reports; open one to read what was filed under it. Naming a bill says the organization lobbied on it, not which side it took.
Health Issuesin 8 report entries · 16 bills named
In its own words
Childrens Hospitals Graduate Medical Education (CHGME) program - Urged increased funding for CHGME to align the program levels with other federal physician training programs.
Continued healthcare access - Advocated for a more resilient healthcare infrastructure and policies that provide the staffing and technological infrastructure necessary to maintain essential services, encouraged continuing funding for Community Health Centers beyond current expiration.
Continued monitoring and encouraged passage of the Biosimilar Red Tape Elimination Act (S.1954).
Continued monitoring and encouraged passage of the Improving Seniors' Timely Access to Care Act (H.R. 3514/S.1816).
Continued monitoring and encouraged passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191).
Continued monitoring and encouraged passage of the Protect Medicaid and Rural Hospitals Act (S.2279) .
Continued monitoring and encouraged passage of the Protecting Health Care and Lowering Costs Act (S.2556).
Continued monitoring and encouraged passage of the Resident Physician Shortage Reduction Act of 2025 (S.2439/H.R.3890/H.R.4731).
Continued monitoring and encouraged passage of the Save Healthcare Workers Act (S.1600/H.R.3178).
Drug Shortages - Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs; issues related to compounding; issues related to buffer inventory.
Encouraged improved stakeholder communication and increased notification by manufacturers for surges in demand.
Continued monitoring and encouraged passage of the Drug Origin Transparency Act of 2026 (HR.8339).
Hospital Data and Analytics - Provided education on the types of clinical, operational, financial and quality data hospitals collect and monitor to improve patient care, including how providers use data to assess and integrate emerging healthcare technologies.
Hospital Group Purchasing - Advocated to highlight the value that hospital group purchasing organizations (GPOs) provide to hospitals and suppliers.
Provided education on how GPOs work in the healthcare supply chain and the role they play in delivering value to healthcare providers, as well as key differences between traditional GPOs and PBMs.
Price Transparency - Encouraged policies that minimize administrative burden on providers associated with implementing and complying with price transparency requirements.
Supply Assurance - Continued advocacy for policies that support resilient healthcare supply chains and help ensure reliable access to critical medical products and supplies.
Urged passage of legislation to reauthorize The Pandemic and All-Hazards Preparedness Act (PAHPA).
Telehealth - Encouraged the adoption of additional permanent telehealth policies to extend certain telemedicine flexibilities beyond their current expiration date.
Workforce - Advocated for strengthening the health workforce and preventing workforce shortages through policies that support education, training, recruitment and retention efforts.
User Fee Acts - Engaged on the User Fee Acts (UFAs) reauthorization process and provided feedback on related policy considerations.
Childrens Hospitals Graduate Medical Education (CHGME) program - Urged increased funding in FY 2027 to fund CHGME with the same priority as other federal physician training programs Continued healthcare access - Advocated for a more resilient healthcare infrastructure and policies that provide the staffing and technological infrastructure necessary to maintain essential services Continued monitoring and encouraged passage of the Biosimilar Red Tape Elimination Act (S.1954) Continued monitoring and encouraged passage of the Improving Seniors' Timely Access to Care Act (H.R. 3514/S.1816) Continued monitoring and encouraged passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191) Continued monitoring and encouraged passage of the Protect Medicaid and Rural Hospitals Act (S.2279) Continued monitoring and encouraged passage of the Protecting Health Care and Lowering Costs Act (S.2556) Continued monitoring and encouraged passage of the Resident Physician Shortage Reduction Act of 2025 (S.2439/H.R.3890/H.R.4731) Continued monitoring and encouraged passage of the Save Healthcare Workers Act (S.1600/H.R.3178).
Drug shortages - Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs; issues related to compounding; issues related to buffer inventory.
Encouraged improved stakeholder communication and increased notification by manufacturers for surges in demand Endorsed and encouraged passage of the Drug Origin Transparency Act of 2026 (HR.8339) Hospital Data and Analytics - Provided education and information on the types of clinical, operational, financial and quality data hospitals collect and monitor to improve patient care.
Supply Assurance - Responded to a Senate Special Committee on Aging inquiry on vulnerabilities in the U.S. pharmaceutical supply chain highlighting the work done by GPOs to improve supply chain resiliency and encouraging additional healthcare supply chain visibility.
Urged passage of legislation to reauthorize The Pandemic and All-Hazards Preparedness Act (PAHPA) Telehealth - Encouraged the adoption of additional permanent telehealth policies to extend certain telemedicine flexibilities beyond their current expiration date.
United States Core Data for Interoperability Draft Version 7 - Respond to the Office of the National Coordinator for Health Information Technology Policy (ONC) on issues raised in Standards Bulletin 2026-1 (SB26-1) and offered comments to constructively improve certain data elements of Draft USCDI v7.
Offered recommendations for future iterations of USCDI standards.
Continued healthcare access - Advocated for a more resilient healthcare infrastructure and policies that provide the staffing and technological infrastructure necessary to maintain essential services Continued monitoring and encouraged passage of the Biosimilar Red Tape Elimination Act (S.1954) Continued monitoring and encouraged passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191) Continued monitoring and encouraged passage of the Protect Medicaid and Rural Hospitals Act (S.2279) Continued monitoring and encouraged passage of the Protecting Health Care and Lowering Costs Act (S.2556) Continued monitoring and encouraged passage of the Resident Physician Shortage Reduction Act of 2025 (S.2439/H.R.3890/H.R.4731) Continued monitoring and encouraged passage of the Save Healthcare Workers Act (S.1600/H.R.3178).
Draft Guidance for Industry, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies (Docket No. FDA-2011-D-0605) - Urging FDA to streamline biosimilar approval for increased patient access to cost-effective treatment alternatives Drug shortages - Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs; issues related to compounding; issues related to buffer inventory.
Encouraged improved stakeholder communication and increased notification by manufacturers for surges in demand Hospital Group Purchasing - Advocated to highlight the value that hospital group purchasing organizations (GPOs) provide to hospitals and suppliers.
Monitored development and introduction of the Drug Origin Transparency Act of 2025 (HR.8339) Monitored development and passage of the Consolidated Appropriations Act, 2026 (H.R. 7148) Payer-mandated White Bagging - Urged support for policy updates related to payer-mandated white bagging for medications
340b drug pricing program.
Health care workforce.
Health care supply chain.
Health care drug shortages.
H.R. 9599 - SECURE 340B Act - Strengthening the Exercise of Controls and Upgrading Requirements of Efficiency in 340B Act.
S. 5244 - SUSTAIN 340B Act - Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act.
340b drug pricing program. Health care workforce. Health care supply chain. Health care drug shortages.
Medicare/Medicaidin 3 report entries · 1 bill named
In its own words
Medicaid Program;
Amending the Indirect Hold Harmless Threshold of Healthcare Related Taxes (CMS-2452-P) - Recommended CMS reconsider certain aspects of the Proposed Rule to prevent unnecessary disruption to state Medicaid programs, Medicaid beneficiaries, and the health systems who serve these patients.
Community Engagement Requirement for Certain Individuals (CMS2454-IFC) - Responded to various issues in the interim final rule with comment period and recommended several modifications to the IFC for CMS to prioritize limiting disruptions to care.
Medicaid Managed Care State Directed Payments and Medicaid Fee For-Service Targeted Medicaid Practitioner Payments (CMS-2449-P) - Responded to various issues and proposals in the proposed rule, urged CMS to reconsider implementation to avoid unnecessary disruption to state Medicaid programs, Medicaid beneficiaries and hospitals.
Medicare and Medicaid Programs;
CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies;
Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program (CMS-1848-P) - Raised concerns with several proposals that would affect payment adequacy and care delivery while voicing support for policies that sustain access to telehealth.
Continued monitoring and encouraged passage of the Medical Supply Chain Resiliency Act (S.998/HR.2213) Provided education and information on the impact of continued tariffs on the healthcare supply chain
Continued monitoring and encouraged passage of the Medical Supply Chain Resiliency Act (S.998/HR.2213)
Not-for-Profit Hospital Tax-exemption - Provided education and information on hospital tax exemption and what is required to justify and maintain tax-exempt status, including particular reporting requirements.
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
Who did the lobbying
The organization’s own reports give its total lobbying costs, including any firms it hired; each firm reports what this client paid it.
Reported twice a year by the lobbying filer. $62.8K is political giving that also appears in FEC filings.
Congressman French Hill$8.5K
Congressman Randy Fine$5.5K
Congresswoman Laurel Lee$5.5K
Congressman Chris Pappas$3.5K
Congressman John Rutherford$3.5K
Congressman Mario Diaz-Balart$3K
Senate candidates$3K
Congressional candidates$2.5K
Congressman Rick Crawford$2.5K
Federal candidates$2.5K
Matched by name: these reports are filed for “VIZIENT, INC.”, found by searching “VIZIENT”. Lobbying and FEC records share no ID, so an organization that lobbies under another name is missed. Source: LDA.gov, accessed Oct 26, 2026. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
Vizient, Inc., PAC is registered with the Federal Election Commission as a PAC (qualified). It is a lobbyist/registrant PAC. Its FEC record names Vizient, Inc. as an affiliate. Official FEC summary: Federal Election Commission committee record.
Pages quoted 0 pages
No pages quoted
Nothing from this committee’s or its sponsor’s site is quoted yet.
Linked public records
No approved organization identity yet
The official FEC committee record remains available under Filings.
TSTerri A. SewellDemocratic · U.S. House · AL-07 · via Terri Sewell For Congress4 payments, latest Jun 16, 2026 · CONTRIBUTION · FEC filing, Jun 16, 2026$10K
JCJohn CornynRepublican · U.S. Senate · TX · via Texans For Senator John Cornyn Inc.2 payments, latest Mar 11, 2026 · CONTRIBUTION · FEC filing, Mar 11, 2026$10K
BDBeth Van DuyneRepublican · U.S. House · TX-24 · via Beth Van Duyne For Congress4 payments, latest Jun 11, 2026 · CONTRIBUTION · FEC filing, Jun 11, 2026$10K
BGBrett GuthrieRepublican · U.S. House · KY-02 · via Guthrie For Congress2 payments, latest Mar 26, 2026 · CONTRIBUTION · FEC filing, Mar 26, 2026$10K
JEJake EllzeyRepublican · U.S. House · TX-06 · via Jake Ellzey For Congress4 payments, latest Jun 11, 2026 · CONTRIBUTION · FEC filing, Jun 11, 2026$10K
People for BenSenate campaign committee · Connected to LUJAN VICTORY FUND · 2 payments
$6K
$277K across 80 recipient committees, or 99% of everything this committee reports spending. The largest 12 are shown.
Built from FEC Schedule A and Schedule B filings for the selected cycle. A committee only appears here if the money was itemized under its FEC committee ID.
Colorado25 contributions · 3.6%
$8,174
Missouri20 contributions · 3.5%
$7,965
Maryland16 contributions · 3%
$6,840
Tennessee17 contributions · 2.9%
$6,720
By the state each contributor wrote on the filing. The FEC aggregates every Schedule A line together, so one committee or organization transfer can account for a whole state. Contributors who have given $200 or less this cycle are not itemized and cannot be placed on a map. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total.
Donors’ employers as filed
Donors’ employers
Employer as filed
Amount
Vizient INC565 contributions · 100% of ranked
$229,771
A further $150 came from donors whose answer names no employer (blank), so it is not ranked. Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($28,490) are not itemized, so no employer or occupation is filed for them.
Donors’ occupations as filed
Donors’ occupations
Occupation as filed
Amount
Managing Director Consulting21 contributions · 4.7% of ranked
$10,850
CFO5 contributions · 3.7% of ranked
$8,400
Chief Customer Officer5 contributions · 3.7% of ranked
$8,400
Chief Legal Officer5 contributions · 3.7% of ranked
$8,400
CPO5 contributions · 3.7% of ranked
$8,400
President & CEO5 contributions · 3.7% of ranked
$8,400
Chief Strategy Officer5 contributions · 3.2% of ranked
$7,328
Group SVP Marketing & Corp Develop2 contributions · 2.1% of ranked
$4,800
A further $150 came from donors whose answer names no occupation (blank), so it is not ranked. Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($28,490) are not itemized, so no employer or occupation is filed for them.
The people, firms and committees paid the most, across every kind of payment. Each share is of everything the committee reported spending this cycle, not only the itemized payments above. A payee that is itself a committee links to its own profile.
Medicare Drug Price Negotiation Program Draft Guidance: Manufacturer Effectuation of the Maximum Fair Price in 2028 - Voiced concerns that retrospective refund models, variable manufacturer processes, and new data and enrollment requirements will create provider burden.
Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program;
Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data;
Prior Authorization;
Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots (CMS-1850-P) - Responded to various issues and proposals in the proposed rule, encouraging CMS to provide a more substantial market basket increase for CY 2027.
Urged CMS to reconsider policies that would increase providers financial instability.
Provider Payment - Supported changes to Medicare/Medicaid provider payment system and increased hospital reimbursements.
Advocated for reimbursement rates that reflect the true cost of care, particularly for hospitals serving vulnerable and rural populations.
Advanced Notice of Proposed Rulemaking: Medicare Program;
Ensuring Safety through Domestic Security with Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals (CMS-1516-ANPRM) - Responded to various issues and proposals provided in the ANPRM, encouraged non-budget neutral Medicare payments to incentivize domestic procurement Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (Docket No.: CMS-2025-1393) - Responded to various issues in the proposed rule regarding the Medicare Advantage/Part C and the Medicare Prescription Drug Benefit (Part D) program and Quality Rating System (Star Ratings).
Global Benchmark for Efficient Drug Pricing (GLOBE) Model Proposed Rule (CMS5545-P) - Responded to various issues and proposals provided in the Proposed Rule, emphasized aligning reimbursement model with performance Monitored development and passage of the Consolidated Appropriations Act, 2026 (H.R. 7148) Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program Proposed Rule (CMS-9883-P) - Responded to various issues and proposals provided in the Proposed Rule Provider payment - Supported changes to Medicare/Medicaid provider payment system and increased hospital reimbursements.
Medicare Program;
Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates;
Requirements for Quality Programs; and Other Policy Changes (CMS-1849-P) - Responded to various issues and proposals in the proposed rule, advocated for a market basket update that more accurately reflects hospitals' cost of providing care in the IPPS Final Rule for FY 2027.
Patient Protection and Affordable Care Act;
Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges (CMS-0062-P) - Responded to various issues in the proposed rule and recommended several modifications related to prior authorization processes to improve implementation and reduce provider burden Provider payment - Supported changes to Medicare/Medicaid provider payment system and increased hospital reimbursements.